Biocon gets European Commission nod for breast cancer biosimilar
First under new tailored clinical pathway; company’s fifth oncology biosimilar approved in Europe and the US
Published
Original News Source
The Hindu BusinessLine
Source Website
www.thehindubusinessline.com ↗
Content & Media Rights
The Hindu BusinessLine
Editorial Publisher
360 NEWS (Independent Media)
360 News
First under new tailored clinical pathway; company’s fifth oncology biosimilar approved in Europe and the US
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

